SUMMARY Three double blind crossover studies were carried out to assess the ability of primed infusions of famotidine to raise intragastric pH over 24 hours in 12 duodenal ulcer patients. pH was measured continuously using intragastric electrodes and solid state recording devices. The studies compared the effects of placebo, famotidine 10 mg bolus injection iv followed by continuous infusions of 3.2 mg/h and 4 mg/h in random order. Gastric acidity decreased significantly with both dose regimens (p<00005) but the effects of either dosage were similar. During fasting median pH rose from 1.35 to 7.1 and 7.05 respectively. During the day, when standard meals were taken, median pH rose from 1.30 to 4-3 and 3.65 respectively. Despite continuous infusions the H2-antagonist was less effective during this time. The latter finding raises questions about gastric secretory control during the day when food is eaten.
Intravenous antisecretory drugs are commonly used in patients with gastrointestinal bleeding,'2 in intensive care units34 and in anaesthesia. '6 The aim of such therapy is to raise the pH of the gastric milieu to a level at which peptic activity is minimal so that clot or mucosal digestion is limited. While it has been suggested that rebleeding from peptic lesions is decreased when pH rises to about pH 4,7 clear evidence that H2-receptor antagonists reduce rebleeding rates or mortality is lacking. A positive trend suggesting efficacy of cimetidine and ranitidine exists' and a possible reason for such limited success is that existing dosage regimens produce less than optimum changes in gastric pH.' It At 0800 a bolus injection was given over two minutes and a continuous infusion was started at a rate of 1 ml/h using mobile rechargeable pumps (Perfusor secura/Braun Melsungen, FRG). The studies were randomised, crossover and double blind. The following regimens were compared: (a) Placebo 10 ml bolus followed by 1 ml/h (normal saline injection); (b) Famotidine 10 mg as a 10 ml bolus followed by 3-2 mg/h (80 mg in 25 ml normal saline); (c) Famotidine 10 mg as a 10 ml bolus followed by 4.0 mg/h (100 mg in 25 ml normal saline).
Routine haematological and biochemical screening and ECG were done before and after each study and 4 hourly blood pressure and pulse measurements were made during the studies.
DATA PROCESSING AND STATISTICAL ANALYSIS Data were transferred via floppy discs to a Harris computer and analysis was only done when all studies were complete. The following time periods were defined for analysis; 24 hours, fasted (0900-1300 h plus 2400-0800 h), and fed (1300-2400 h). Percentage of time with pH above 5.0 and 6-0 were defined as the primary and secondary variables of interest for statistical comparisons. Wilcoxon's signed rank tests were used for the above comparisons between all study days. Probability values of p<005 were considered significant.
Results
The study was well tolerated and no side effects of drug administration were noted. Electrocardiographic abnormalities and significant changes in haematological and biochemical profiles were not seen. No studies were repeated through inadequate electrode function but one day's data from one patient were lost because it was not able to be transferred from the recording device.
The mean age of the 12 patients (seven men, five women) was 45 (range 20-65) years (nine smokers, three non-smokers).
Figures la (placebo), b (famotidine 3-2 mg/h), and c (famotidine 4 Figure 3 . The Table shows the percentage of time pH was above the predefined levels of 5.0 and 6-0 during these time periods. Significantly reduced acidity was found with both doses compared with placebo during all time periods (p<0.0001) but the small differences between the higher and lower famotidine doses were never statistically significant.
Discussion
The aim of this study was to investigate whether it was possible to raise intragastric pH to concentrations above 5.0 throughout a 24 hour period with continuous infusion of a potent H2-receptor antagonist. We used higher doses than those recommended for standard duodenal ulcer therapy because we were aware of difficulties others had experienced in attempts to produce prolonged anacidity in patients with H2-receptor antagonists. l(L12 The doses used here are similar in terms of potency to those used previously' when cimetidine 100 mg/h would not maintain pH above 4.0 in over 10% of acutely ill patients. We wanted to raise pH consistently above 5 or even higher so as to limit peptic activity which may be important for prevention of stress ulceration,4' 21 and prevent clot digestion which might be important in gastrointestinal bleeding. 22 We have shown consistent responses of duodenal ulcer patients to continuous infusions of famotidine. The change in pH we have measured is of similar order to that observed during intravenous omeprazole therapy.23 Primed infusions (10 mg followed by 3.2 mg/h) raised gastric pH well into the target range 454 group.bmj.com on October 14, 2017 -Published by http://gut.bmj.com/ Downloaded from Continuous intravenous infusions offamotidine maintain high intragastric pH in duodenal ulcer 8 10 12 14 16 18 20 22 24 2 4 6 Time (h) 
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when patients were not fed. Most patients on intensive care units and many patients with significant gastrointestinal haemorrhage are kept 'nil by mouth' and for these this dosage regimen should prove effective providing extrapolation from our controlled circumstances is valid. From our results, additional clinical benefit from higher dose infusions would not be expected. In these studies we chose to feed the patients standard meals. In some countries patients admitted with gastrointestinal haemorrhage are not denied food and as far as possible we tried to simulate clinical circumstances. It was also felt that bleeding itself may provide a stimulus to gastric secretion similar to that of a high protein meal. We realised that eating may stimulate gastric acidity and affect the responses of patients to a continuous infusion of an H2-receptor antagonist and therefore predefined fasting and fed periods for separate analysis. We were, however, surprised by the magnitude of the change which followed food. The return of acidity occurred in the patients despite continuous infusions of famotidine which had produced virtual anacidity before eating and is best seen in Figures 2 and 3 3.
investigations are required to identify the mechanisms which limit the antisecretory effects of H2-receptor antagonists and which seem prominent during the day when people eat.
